HIV protein switch may help virus squeeze into host cell nucleus
Supercomputer simulations have revealed how changes in the shape of the HIV-1 capsid protein may help the virus squeeze its ...
Utah Public Radio2d
A breakthrough HIV drug was developed using Utah biochemistry research
An HIV drug was named “2024 Breakthrough of the Year” by Science Magazine. Biochemistry research from the University of Utah ...
Hosted on MSN2mon
Sangamo to receive $20M from Astellas Pharma in capsid license agreement
Astellas Pharma (ALPMY) and Sangamo (SGMO) announced they have entered into a license agreement allowing Astellas to leverage Sangamo’s neurotropic adeno-associated virus capsid, STAC-BBB ...
Drug therapy lenacapavir may effectively control HIV in Uganda
A multi-national, multi-institutional study led by Weill Cornell Medicine investigators found little natural resistance to a ...
GlobalData on MSN2d
Gilead’s lenacapavir moves closer to FDA approval for HIV PrEP use
Lenacapavir is already approved under the name Sunlenca as an HIV treatment for patients resistant to other medication ...
News Medical on MSN1d
New HIV therapy lenacapavir shows high efficacy in Ugandan population
A multi-national, multi-institutional study led by Weill Cornell Medicine investigators found little natural resistance to a ...
ALS News Today1d
Voyager Therapeutics reassesses SOD1-ALS gene therapy program
The company will discontinue development of its original ALS gene therapy candidate VY9323 amid toxic effects in nonhuman ...
EurekAlert!2d
New therapy may effectively control HIV in Uganda
A multi-national, multi-institutional study led by Weill Cornell Medicine investigators found little natural resistance to a ...
EurekAlert!1d
New Therapy May Effectively Control HIV in Uganda (IMAGE)
Transmission electron micrograph of HIV-1 virus particles (teal) exiting an infected immune cell after replicating inside the cell. Inset: Interior view a HIV-1 virus showing the capsid (yellow) that ...